-
Draupnir Holdings Ltd have officially merged with Nordic Group B.V
-We are pleased to announce that as of January 2023, Draupnir Holdings Ltd which incorporates Altacor, ParaPharm Development & Transdermal…
0 -
Nordic Pharma files submission to health Canada for the marketing authorization of methotrexate autoinjector for treating rheumatoid arthritis in Canada
-Canada, March 29, 2022 – NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug…
-
European Commission approves Teysuno in metastatic colorectal cancer
-Nordic Pharma announces that on the 24th of January, the European Commission (EC) approved the new indication for Teysuno® (tegafur/gimeracil/oteracil)…
-
Positive EMA opinion for the use of Teysuno in metastatic colorectal cancer
-Nordic Pharma has announced that on 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a…
-
Nordic Pharma present at CPhI !
-Nordic Pharma will be attending CPhI Worldwide in Milan, Italy from November 9th-11th 2021. We are actively looking for late stage partnering…
-
New Headquarters Offices
-Both of Nordic Pharma HQs, located in France and in the Netherlands, have recently moved. Nordic Pharma HQ NL has…
